NCT04218084: A reported trial by Pfizer
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04218084 |
|---|---|
| Title | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants With Sickle Cell Disease (HOPE Kids 2) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 11, 2020 |
| Completion date | Jan. 18, 2024 |
| Required reporting date | Jan. 18, 2027, midnight |
| Actual reporting date | May 29, 2025 |
| Date last checked at ClinicalTrials.gov | April 29, 2026 |
| Days late | None |